{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Hits New 52-Week High of $73.92
Ionis Pharmaceuticals, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals sector. The company reported significant growth in net sales and stock value over the past year, supported by high institutional holdings and improved operational efficiency amid declining raw material costs.
Ionis Pharmaceuticals Hits New 52-Week High of $72.15
Ionis Pharmaceuticals, Inc. achieved a new 52-week high of USD 72.15 on October 14, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 243.47% increase in net sales, reaching USD 452.05 million, and has demonstrated significant stock growth over the past year.
Ionis Pharmaceuticals Hits New 52-Week High of $71.87
Ionis Pharmaceuticals, Inc. achieved a new 52-week high of USD 71.87 on October 8, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 243.47% increase in net sales, reaching USD 452.05 million, despite facing challenges such as negative return on equity and high institutional ownership.
Ionis Pharmaceuticals Hits New 52-Week High of $70.14
Ionis Pharmaceuticals, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals sector. The company reported a substantial increase in net sales and recorded its highest operating cash flow. With impressive stock performance and high institutional holdings, Ionis is well-positioned in its industry.
Ionis Pharmaceuticals Hits New 52-Week High of $69.25
Ionis Pharmaceuticals has achieved a new 52-week high, reflecting its strong performance in the biotechnology sector. The company reported a substantial increase in net sales and a decrease in raw material costs, while maintaining full institutional ownership, indicating confidence in its strategic direction despite ongoing losses.
Ionis Pharmaceuticals Hits New 52-Week High of $66.23
Ionis Pharmaceuticals, Inc. achieved a new 52-week high of USD 66.23 on October 1, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported a 65.37% increase in stock performance over the past year and a significant 243.47% growth in net sales, reaching USD 452.05 million.
Ionis Pharmaceuticals Hits New 52-Week High of $65.55
Ionis Pharmaceuticals, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company reported significant growth in net sales and stock value over the past year, alongside high institutional holdings, indicating investor confidence despite ongoing losses.
Is Ionis Pharmaceuticals, Inc. technically bullish or bearish?
As of July 7, 2025, Ionis Pharmaceuticals shows a bullish technical trend supported by positive MACD and moving averages, but caution is advised due to bearish RSI readings despite strong recent performance compared to the S&P 500.
Is Ionis Pharmaceuticals, Inc. overvalued or undervalued?
As of February 22, 2023, Ionis Pharmaceuticals is considered risky and overvalued due to a high Price to Book Value of 11.81, a negative ROE of -94.65%, and a low EV to EBITDA ratio of -11.71, despite a strong recent stock return of 76.60%.
Is Ionis Pharmaceuticals, Inc. overvalued or undervalued?
As of February 22, 2023, Ionis Pharmaceuticals is considered overvalued and risky due to significant negative financial metrics, including a P/E ratio of -12.78, compared to healthier ratios of its peers, and despite a recent 6.90% stock return, it underperforms the S&P 500 over longer periods.
Is Ionis Pharmaceuticals, Inc. technically bullish or bearish?
As of April 30, 2025, Ionis Pharmaceuticals, Inc. has a mildly bearish trend influenced by daily moving averages, despite some bullish signals from weekly indicators and mixed signals across time frames.
Who are in the management team of Ionis Pharmaceuticals, Inc.?
As of March 2022, the management team of Ionis Pharmaceuticals, Inc. includes Dr. Stanley Crooke (Executive Chairman), Dr. Brett Monia (CEO), and several directors, including Ms. Joan Herman, Ms. B. Lynne Parshall, Dr. Spencer Berthelsen, Mr. Breaux Castleman, and Dr. Michael Hayden.
What does Ionis Pharmaceuticals, Inc. do?
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics and reported net sales of $132 million with a net loss of $147 million as of March 2025. The company has a market cap of approximately $5.75 billion and does not pay dividends.
How big is Ionis Pharmaceuticals, Inc.?
As of Jun 18, Ionis Pharmaceuticals, Inc. has a market capitalization of $5.75 billion, with net sales of $717.67 million and a net profit of -$457.69 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
